A Agilent Technologies Inc.

Agilent’s 2022 ESG Report Shows Progress Helping Customers Reach Their Sustainability Goals

Agilent Technologies Inc. (NYSE: A) today released its on the company’s work supporting customers with their sustainability initiatives while advancing its own internal high-priority ESG programs, from reducing Scope 3 emissions in the value chain to cultivating a talented, diverse, and inclusive workforce.

This press release features multimedia. View the full release here:

“Agilent is committed to our customers’ success at every stage of their journey to bring great science to life,” said Agilent President and CEO Mike McMullen. “That includes helping them achieve their sustainability goals with our products, technology, and services. At the same time, we’re driving ESG objectives within our operations by fostering a great workplace, and investing in a diverse pipeline of talent, which is essential to our company’s future.”

also covers the role of Agilent products and technology in addressing some of society’s biggest challenges—from improving outcomes for cancer patients to helping measure exposure to substances such as PFAS.

Below are some of the highlights from fiscal 2022 in four focus areas of Agilent’s ESG program:

People

  • Earned Great Place to Work® certification in more than 20 countries and territories, based on strong results from an independent survey of employees.
  • Contributed $1 million to Delaware State University, a historically Black university, to fund scholarships for students pursuing STEM degrees; pledged an additional $3.5 million worth of state-of-the art instruments and supplies to equip the university’s new lab.
  • Launched two new employee networking groups (ENGs) to support both Hispanic and Asian Pacific Islander employees, adding to existing networking groups at Agilent to support Black, veteran, women, and LGBTQ+ employees.
  • Increased spending with diverse suppliers by 47 percent year over year, a key element of Agilent’s supplier diversity program.

Planet

  • Engaged suppliers in a plan to reduce Scope 3 emissions and submitted emissions-reduction targets to the Science Based Targets initiative for validation.
  • Reduced energy and water consumption intensity by 9.5 percent and 27.6 percent respectively, exceeding our targets in both areas.
  • Achieved 94 percent diversion of solid waste.
  • Launched a product life cycle assessment pilot study of an Agilent liquid chromatography instrument.
  • Implemented a formal sustainability function in Agilent’s Order Fulfillment division, which embeds sustainability into all aspects of manufacturing, supply chain, and logistics.

Products

  • Expanded sustainability offerings for our customers, including:
    • increasing the number of instruments that have earned the My Green Lab Accountability, Consistency, and Transparency (ACT) label;
    • adding How2Recycle labeling to product packaging;
    • achieving My Green Lab certification of Agilent customer demonstration labs;
    • introducing the HydroInert source for GC/MS, which runs on renewable hydrogen as the carrier gas, in place of non-renewable helium gas; and,
    • offering asset performance management software that can reduce lab energy use.
  • Refurbished 4,300 lab instruments through our award-winning Certified Pre-Owned Instruments Program, keeping decommissioned instruments out of landfills and substantially extending their life.

Prosperity

  • Invested $725 million in Agilent’s Frederick, Colorado, manufacturing facility to double production of therapeutic nucleic acids, which is expected to generate more than 160 life science jobs.
  • Donated $7.5 million in cash and in-kind contributions to support graduate students in STEM disciplines and academics working on innovative research that aligns with Agilent’s mission and business strategy.
  • Invested $7 million to upgrade Agilent’s R&D labs in Little Falls, Delaware, adding jobs to Agilent’s workforce in the state.

Agilent’s 2022 report also includes an updated Task Force on Climate-Related Financial Disclosures (TCFD) report, an index of materially relevant topics from the Global Reporting Initiative (GRI), and a SASB index. Read the report and related materials about Agilent’s ESG program at

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on and .

EN
31/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch